Monoclonal antibodies and hybridomas producing them that interact with
osteoprotegerin ligand (OPGL) are provided. Methods of treating
osteopenic disorders by administering a pharmaceutically effective amount
of antibodies to OPGL are also provided. Methods of detecting the amount
of OPGL in a sample using antibodies to OPGL are further provided.
